| Biologic naïve (N = 574) | TNFi-exposed (N = 2451) | p-value | ||||
---|---|---|---|---|---|---|---|
n | % | n | % | ||||
Female, n (%) | 402 | 70 | 1810 | 73.9 | 0.06 | ||
Rheumatoid factor positive (n = 444:1925) | 386 | 84.9 | 1625 | 82 | 0.012 | ||
Cyclic citrullinated peptide (CCP) + ve (n = 13:109) | 10 | 76.9 | 74 | 67.9 | 0.51 | ||
No. of prior DMARDs |  |  |  |  | < 0.001 | ||
 None | 31 | 5.4 | 200 | 8.2 |  | ||
 1 | 95 | 16.6 | 53 | 2.2 |  | ||
 2 | 154 | 26.5 | 132 | 5.4 |  | ||
 3 | 115 | 20 | 408 | 16.7 |  | ||
 4 | 92 | 16 | 628 | 25.6 |  | ||
 5 | 59 | 10.3 | 583 | 23.8 |  | ||
 6–10 | 28 | 4.9 | 447 | 18.2 |  | ||
Ever used methotrexate | 493 | 85.9 | 2185 | 89.2 | 0.03 | ||
Ever used prednisolone | 318 | 55.4 | 1933 | 78.9 | < 0.001 | ||
Current smoker | 78 | 13.6 | 341 | 14.1 | 0.76 | ||
Prior malignancy | 44 | 7.4 | 94 | 3.7 | < 0.001 | ||
 | N | Mean | SD | N | Mean | SD | p-value |
Age (years) | 574 | 62.4 | 12.3 | 2451 | 55.7 | 12.4 | < 0.001 |
HAQ (Range 0–3) | 572 | 1.1 | 0.7 | 2443 | 1.2 | 0.7 | < 0.001 |
AQoL (Range − 0.04 – 1) | 572 | 0.6 | 0.3 | 2438 | 0.5 | 0.2 | < 0.001 |
EQ5D (UK) (Range − 0.59 - 1) | 560 | 0.7 | 0.3 | 2405 | 0.6 | 0.3 | < 0.001 |
PCS (Range 0–100) | 556 | 35.1 | 11.2 | 2374 | 32.1 | 11 | < 0.001 |
MCS (Range 0–100) | 556 | 48.3 | 11.6 | 2374 | 46.5 | 11.9 | 0.001 |
ESR (Range 2–109) | 150 | 26.3 | 22.1 | 1259 | 33.2 | 25.1 | 0.002 |
CRP (Range 0.4–128) | 155 | 17.1 | 22.6 | 1260 | 25.3 | 30.1 | 0.001 |
Joint count (Range 0–50) | 150 | 12.2 | 12.8 | 1323 | 23.5 | 11 | 0.001 |
Years since RA diagnosis | 566 | 13.8 | 11.6 | 2444 | 14.1 | 10.6 | 0.1 |